ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference where our CEO, James Westcott, presented our groundbreaking data in a scientific poster.
Our team and network of academic institutions, research organizations, and industry partners have been developing and testing our innovative approach of antagonising GPR35 to tackle digestive diseases with high unmet clinical need, including cancer, since 2021.
These collective efforts, employing state-of-the-art methodologies and data analysis techniques, have uncovered unique insights and we’re excited about the impact our work could have on patients and beyond.
Our poster, which generated significant academic and industry interest, provided a glimpse into the mechanisms by which GPR35 modulation impacts cancer development and progression, findings that could revolutionize our understanding of this complex disease.
If you’re interested in learning more about ThirtyFiveBio and our groundbreaking data presented at AACR 2023, we encourage you to get in touch with us via email@example.com.